In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627.
In in vitro susceptibility tests the new carbapenem LJC10,627 showed potent antibacterial activity against gram-positive and gram-negative bacteria, except that most methicillin-resistant Staphylococcus aureus strains tested were found to be resistant to LJC10,627. LJC10,627 showed high activity against Pseudomonas aeruginosa and was active against Enterobacter cloacae and Citrobacter freundii strains which were resistant to ceftazidime and cefpirome. The Ki values of LJC10,627 for penicillinase Type I, cephalosporinase and oxyiminocephalosporinase were low, whereas the Ki value for L-1 enzyme from Xanthomonas maltophilia was high.
Episome Institute, Gunma, Japan.
M
M
Yoshida
S
S
Mitsuhashi
D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D015780:Carbapenems / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D015394:Molecular Structure; D013845:Thienamycins; D001618:beta-Lactamases / Q000378:metabolism*; D000097572:Cefpirome
D015780:Carbapenems; D002442:Ceftazidime; D002511:Cephalosporins; D015378:Imipenem; D013845:Thienamycins; D001618:beta-Lactamases; D000097572:Cefpirome; C039536:panipenem; C065257:biapenem